Biology Reference
In-Depth Information
98. Kaiser J. Gene therapy. Seeking the cause of induced leukemias in
X-SCID trial.
Science
2003;
114. Davis BM, Roth JC, Liu L, et al. Characterization of the P140K,
PVP(138
(5606). 495.
99. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of
gene therapy for SCID.
Nat Immunol
2010;
299
140)MLK, and G156A O6-methylguanine-DNA meth-
yltransferase mutants: implications for drug resistance gene
therapy.
Hum Gene Ther
1999;
e
60.
100. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integra-
tion, and sustained long-term expression of the transgene in
adult rat brains injected with a lentiviral vector.
Proc Natl Acad
Sci, USA
1996;
(6):457
11
e
78.
115. Cai S, Xu Y, Cooper RJ, et al. Mitochondrial targeting of human
O6-methylguanine DNA methyltransferase protects against cell
killing by chemotherapeutic alkylating agents.
Cancer Res
2005;
10
(17):2769
e
8.
101. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and
stable transduction of nondividing cells by a lentiviral vector.
Science
1996;
(21):11382
93
e
27.
116. Sorg UR, Kleff V, Fanaei S, et al. O6-methylguanine-DNA-meth-
yltransferase (MGMT) gene therapy targeting haematopoietic
stem cells: studies addressing safety issues.
DNA Repair (Amst)
2007;
65
(8):3319
e
7.
102. De Palma M, Montini E, Santoni de Sio FR, et al. Promoter
trapping reveals significant differences in integration site selec-
tion between MLV and HIV vectors in primary hematopoietic
cells.
Blood
2005;
(5259):263
2
e
209.
117. Davis BM, Reese JS, Lingas K, et al. Drug selection of mutant
methylguanine methyltransferase from different oncoretroviral
backbones results in multilineage hematopoietic transgene
expression in primary and secondary recipients.
J Hematother
Stem Cell Res
2003;
6
(8):1197
e
15.
103. Laufs S, Nagy KZ, Giordano FA, et al. Insertion of retroviral
vectors in NOD/SCID repopulating human peripheral blood
progenitor cells occurs preferentially in the vicinity of transcrip-
tion start regions and in introns.
Mol Ther
2004;
(6):2307
105
e
87.
118. Reese JS, Koc ON, Lee KM, et al. Retroviral transduction of
a mutant methylguanine DNA methyltransferase gene into
human CD34 cells confers resistance to O6-benzylguanine plus
1,3-bis(2-chloroethyl)-1-nitrosourea.
Proc Natl Acad Sci, USA
1996;
(4):375
12
e
81.
104. Hanania EG, Fu S, Zu Z, et al. Chemotherapy resistance to taxol
in clonogenic progenitor cells following transduction of CD34
selected marrow and peripheral blood cells with a retrovirus that
contains the MDR-1 chemotherapy resistance gene.
Gene Ther
1995;
10
(5):874
e
93.
119. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT
into human CD34(
(24):14088
93
e
94.
105. Rattmann I, Kleff V, Sorg UR, et al. Gene transfer of cytidine
deaminase protects myelopoiesis from cytidine analogs in an in
vivo murine transplant model.
Blood
2006;
2
(4):285
e
) hematopoietic progenitors at low multi-
plicity of infection confers significant resistance to BG/BCNU
and allows selection in vitro.
Mol Ther
2002;
þ
71.
106. Blakley RL, Sorrentino BP. In vitro mutations in dihydrofolate
reductase that confer resistance to methotrexate: potential for
clinical application.
Hum Mutat
1998;
(9):2965
108
e
7.
120. Zielske SP, Reese JS, Lingas KT, et al. In vivo selection of
MGMT(P140K) lentivirus-transduced human NOD/SCID repo-
pulating cells without pretransplant irradiation conditioning.
J Clin Invest
2003;
(4):381
5
e
63.
107. Capiaux GM, Budak-Alpdogan T, Alpdogan O, et al. Protection
of hematopoietic stem cells from pemetrexed toxicity by retro-
viral gene transfer with a mutant dihydrofolate reductase-mutant
thymidylate synthase fusion gene.
Cancer Gene Ther
2004;
(4):259
11
e
70.
121. Lin Y, Cheung P, Roth JC, et al. Imaging stem cell-derived
persistent foci after in vivo selection of lentiviral MGMT-P140K
transduced murine bone marrow cells.
Mol Ther
[Epub ahead of
print 8 February 2011].
122. Gerull S, Beard BC, Peterson LJ, et al. In vivo selection and che-
moprotection after drug resistance gene therapy in a non-
myeloablative allogeneic transplantation setting in dogs.
Hum
Gene Ther
2007;
(10):1561
112
e
(12):
11
73.
108. Allay JA, Dumenco LL, Koc ON, et al. Retroviral transduction
and expression of the human alkyltransferase cDNA provides
nitrosourea resistance to hematopoietic cells.
Blood
1995;
767
e
(11):
85
51.
109. Moritz T, Mackay W, Glassner BJ, et al. Retrovirus-mediated
expression of a DNA repair protein in bone marrow protects
hematopoietic cells from nitrosourea-induced toxicity in vitro
and in vivo.
Cancer Res
1995;
3342
e
6.
123. Larochelle A, Choi U, Shou Y, et al. In vivo selection of hema-
topoietic progenitor cells and temozolomide dose intensification
in rhesus macaques through lentiviral transduction with a drug
resistance gene.
J Clin Invest
2009;
(5):451
18
e
14.
110. Pegg AE, Swenn K, Chae MY, et al. Increased killing of prostate,
breast, colon, and lung tumor cells by the combination of inac-
tivators of O6-alkylguanine-DNA alkyltransferase and N, N'-
bis(2-chloroethyl)-N-nitrosourea.
Biochem Pharmacol
1995;
(12):2608
55
e
63.
124. Trobridge G, Beard BC, Kiem HP. Hematopoietic stem cell
transduction and amplification in large animal models.
Hum Gene
Ther
2005;
(7):1952
119
e
50
(8):
66.
125. Milsom MD, Williams DA. Live and let die: in vivo selection of
gene-modified hematopoietic stem cells via MGMT-mediated
chemoprotection.
DNA Repair (Amst)
2007;
16
(12):1355
e
8.
111. Kanzawa T, Bedwell J, Kondo Y, et al. Inhibition of DNA repair
for sensitizing resistant glioma cells to temozolomide.
J Neurosurg
2003;
1141
e
21.
126. Cornetta K, Croop J, Dropcho E, et al. A pilot study of dose-
intensified procarbazine, CCNU, vincristine for poor prognosis
brain tumors utilizing fibronectin-assisted, retroviral-mediated
modification of CD34
(8):1210
6
e
52.
112. Crone TM, Goodtzova K, Edara S, et al. Mutations in human O6-
alkylguanine-DNA alkyltransferase imparting resistance to O6-
benzylguanine.
Cancer Res
1994;
99
(6):1047
e
7.
113. Xu-Welliver M, Kanugula S, Pegg AE. Isolation of human O6-
alkylguanine-DNA alkyltransferase mutants highly resistant to
inactivation by O6-benzylguanine.
Cancer Res
1998;
(23):6221
54
e
peripheral blood cells with O6-methyl-
guanine DNA methyltransferase.
Cancer Gene Ther
2006;
þ
13
(9):
(9):1936
45.
886
95.
58
e
e
